The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File photo

July 29 (Reuters) – Second-quarter sales of AstraZeneca’s (AZN.L) COVID-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on Thursday again delayed its U.S. application for approval as it gathers more data for submissions.

The vaccine has been touted as a major weapon against the pandemic because it is cheaper and easier to use than some rivals. AstraZeneca and its Indian manufacturing partner say they have supplied a billion doses to 170 countries so far.

The company began work on the vaccine last year after teaming up with the University of Oxford, despite having no prior vaccine experience.

But the shot has also faced setbacks, including disputes over data, production problems, and links to rare side-effects that have led some countries to stop or restrict its use. The United States has been particularly critical of the vaccine.

AstraZeneca said on Thursday it now expected to seek U.S. approval for the vaccine in the second half of this year, and it still hopeful the shot will have a role to play there. Previously, it had planned an application during the first half. read more

A senior executive separately told Reuters that the company was exploring options for the future of its COVID-19 vaccine business, with more clarity on the matter expected by the end of the year. read more

Elsewhere, AstraZeneca is hoping for a boost from the recent purchase of rare medicines business Alexion.

Including Alexion, it now expects total revenue to increase by a low-twenties percentage this year, and core earnings of $5.05 to $5.40 per share. The forecasts do not include sales from the vaccine.

AstraZeneca shares fell 1.4% in early trade but had recovered the losses and edged higher by 1109 GMT.

VACCINE WOES

The Anglo-Swedish drugmaker is also hoping to settle legal proceedings with the European Commission over vaccine delivery commitments. read more

Despite setbacks, the company said the vaccine, Vaxzevria, brought in $1.17 billion in sales in the first six months of year, putting it among its best selling products, behind first-placed lung cancer drug Tagrisso on $2.54 billion.

Vaccine sales were based on deliveries of about 319 million doses, it said, giving an average price of about $3.7 per dose. Deliveries from its partner, India-based Serum Institute, were not included.

AstraZeneca has said it will not make a profit from the shot during the pandemic but hopes to eventually generate earnings to make the business sustainable. Costs related to the vaccine shaved a cent off second-quarter earnings per share. That was down from 3 cents in the previous three months.

The company said it was also looking into how long the vaccine’s protection lasts and if a booster dose would be needed to keep up immunity.

“People received their second dose, at the earliest in March/April this year, so we need more time to know whether the protection is lasting or needs boosting,” CEO Pascal Soriot said at a media briefing.

While AstraZeneca did not forecast vaccine sales for the year, rivals Pfizer (PFE.N), Moderna (MRNA.O) and Johnson & Johnson (JNJ.N) have guided to $33.5 billion, $19.2 billion and $2.5 billion for their COVID-19 shots, respectively. read more

Total revenue of $8.22 billion for the three months to June beat analysts’ consensus forecast of $7.58 billion. But core earnings of 90 cents per share fell short of an estimated 92 cents.Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout in London Editing by Mark Potter, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles.

Source: https://www.reuters.com/world/uk/astrazeneca-covid-vaccine-sales-jump-894-mln-updates-forecasts-2021-07-29/

You May Also Like

China’s new private tutoring rules put billions of dollars at stake

China’s sweeping new rules in private tutoring has left private education firms facing a significant business impact as Beijing steps up regulatory oversight of a $120 billion industry that investors had bet billions of dollars on in recent years.

Crypto firms drop British registration bids amid scrutiny

A growing number of crypto asset firms are abandoning attempts to register with Britain’s financial regulator as global scrutiny of the rapidly-growing sector intensifies.

EU countries approve landmark climate change law

European Union countries on Monday gave the final seal of approval to a law to make the bloc’s greenhouse gas emissions targets legally binding, as EU policymakers prepare a huge new package of policies to fight climate change.